What is the NOAEL for 3,3,5-Trimethylcyclohexyl salicylate?
3,3,5-Trimethylcyclohexyl salicylate has 100 NOAEL studies in the database. The lowest reported value is 0 % via Dermal in Human. Source: NTP_ICE_skin_sensitization.
Also known as: 3,3,5-Trimethylcyclohexylsalicylate (Homosalate), Homosalate, Benzoic acid, 2-hydroxy-, 3,3,5-trimethylcyclohexyl ester, Caswell No. 482B, Coppertone (+10 more)
CAS 118-56-9
3,3,5-Trimethylcyclohexyl salicylate (CAS 118-56-9) is a chemical substance. Key regulatory status: REACH registered, 7 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, SCCS, ECHA REACH.
3,3,5-Trimethylcyclohexyl salicylate is classified GHS CMR hazard (H315, H319, H335, H361d, H410) in the chemicals database but is restricted in EU cosmetics at max 7.34%.
CAS, identifiers, formula, and alternate names for the matched substance record.
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| Europe; Personal care | European Commission | CosIng |
| Canada; consumer_product; Substances in Products - Canada (4/2014) | Government of Canada | CPCat |
| inert_ingredient; non_food_use; Pesticides | EPA | CPCat |
| IFRA Transparency | IFRA | IFRA |
| pharmaceutical | US International Trade Commission | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 0.5 | % | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 9 | - | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 10 | mg/kg bw/day | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 43 | mg/kg/day | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 75 | mg/kg | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 75 | mg/kg bw/d | - | - | human | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 75 | mg/kg bw/d | - | - | human | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 100 | mg/kg bw | - | - | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 120 | mg/kg bw/d | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 300 | mg/kg bw/day | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 31.3030061241923 | uM | AC50 | - | - | NTP_ICE_endocrine |
| 15.3394006763907 | uM | ACC | - | - | NTP_ICE_endocrine |
| =16.09 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB_GESTIS_DNEL |
| V06SV4M95S | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| V06SV4M95S | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| V06SV4M95S | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| V06SV4M95S | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| - | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| >5000 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =750 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_EPA_TSCA_8e |
| =300 | mg/kg bw/day | LOAEL | oral | Rat | ToxValDB_EPA_TSCA_8e |
| - | unitless | Model Score | - | - | NTP_ICE_endocrine |
| 0.0217 | unitless | Model Score | - | - | NTP_ICE_endocrine |
| =0.5 | % | NOAEL | oral | - | SCCS_vision_codex |
| =0.5 | % | NOAEL | oral | - | SCCS_vision_codex |
| =0.5 | % | NOAEL | oral | - | SCCS_vision_codex |
| =0.5 | % | NOAEL | oral | - | SCCS_vision_codex |
| =2 | % | NOAEL | oral | human | SCCS_vision_codex |
| =2 | % | NOAEL | oral | human | SCCS_vision_codex |
| =2 | % | NOAEL | oral | human | SCCS_vision_codex |
| =2 | % | NOAEL | oral | human | SCCS_vision_codex |
| =9 | - | NOAEL | - | - | SCCS_vision_codex |
| =9 | - | NOAEL | - | - | SCCS_vision_codex |
| =9 | - | NOAEL | - | - | SCCS_vision_codex |
| =9 | - | NOAEL | - | - | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =10 | mg/kg bw/d | NOAEL | oral | rat | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =10 | mg/kg bw/d | NOAEL | oral | rat | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =10 | mg/kg bw/d | NOAEL | oral | rat | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =10 | mg/kg bw/d | NOAEL | oral | rat | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | - | SCCS_vision_codex |
| =20 | mg/kg bw/d | NOAEL | oral | rat | SCCS_vision_codex |
| =20 | mg/kg bw/d | NOAEL | oral | rat | SCCS_vision_codex |
| =20 | mg/kg bw/d | NOAEL | oral | rat | SCCS_vision_codex |
Showing 50 of 100 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | Homosalate | 204-260-8 | ECHA overview → |
Australian industrial chemicals inventory status and applicable conditions.
EU Scientific Committee opinions tied to the matched substance.
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCS/1638/21 | 2 December 2021 | safe with restrictions | up to 7.34% | Potential endocrine disrupting properties; reproductive toxicity concerns from OECD 422 study; assessment covers dermal application only |
| SCCS/1622/20 | 24-25 June 2021 | safe with restrictions | up to 0.5% (full body products); 7.34% established in subsequent SCCS/1638/21 | Potential endocrine disrupting properties (equivocal evidence); reproductive/developmental toxicity based on LOAEL 60 mg/kg bw/d; MoS insufficient at 10% |
| SCCP/1039/06 | 21 March 2007 | safe | up to 10% | No significant endocrine disrupting properties identified at time of opinion (2007); MoS >100 based on NOAEL of 100 mg/kg bw/d from 14-day study; subsequently found insufficient by SCCS/1622/20 |
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
3,3,5-Trimethylcyclohexyl salicylate has 100 NOAEL studies in the database. The lowest reported value is 0 % via Dermal in Human. Source: NTP_ICE_skin_sensitization.
3,3,5-Trimethylcyclohexyl salicylate appears on 6 regulatory/inventory lists including Europe; Personal care, Canada; consumer_product; Substances in Products - Canada (4/2014), inert_ingredient; non_food_use; Pesticides, and 3 more. Source: EPA CPDat.
Yes, 3,3,5-Trimethylcyclohexyl salicylate is also indexed as a cosmetic ingredient under the name Homosalate. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
3,3,5-Trimethylcyclohexyl salicylate is classified GHS CMR hazard (H315, H319, H335, H361d, H410) in the chemicals database but is restricted in EU cosmetics at max 7.34%.
3,3,5-Trimethylcyclohexyl salicylate also appears in cosmetics, pharmaceutical databases.